Reference 2018-367

REF:         2018-367  

Subject:     Psoriasis patients  

          

 

 

Request:

Within your Trust and over the last three months, how many Psoriasis [PsO] patients have been initiated on their first advanced therapy (i.e. Biologic, Apremilast or Dimethyl fumarate)?

Total New Advanced Therapy patient Initiations.

Where possible please split by treatment;

 

Adalimumab [Humira],

Apremilast [Otezla],

Brodalumab [Kyntheum],

Certolizumab [Cimzia],

Dimethyl fumarate [Skilarence],

Etanercept [Enbrel],

Etanercept Biosimilar,Guselkumab [Tremfya],

Infliximab [Remicade],

Infliximab Biosimilar Ixekizumab [Taltz],

Secukinumab [Cosentyx],

Ustekinumab [Stelara]

 

 

Response:

We do not record this information for specific ailments.